Myelodysplastic Syndrome With Excess Blasts-2 (MDS-EB-2) Completed Phase 2 Trials for Sirolimus (DB00877)

Also known as: Myelodysplastic Syndrome With Excess Blasts-2

IndicationStatusPhase
DBCOND0092771 (Myelodysplastic Syndrome With Excess Blasts-2 (MDS-EB-2))Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02756572Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid NeoplasmsTreatment